Clinical Trial Detail

NCT ID NCT04077463
Title A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Participants With Advanced Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Pharmaceutical K.K.
Indications

lung non-small cell carcinoma

Therapies

JNJ-61186372 + Lazertinib

Lazertinib

Age Groups: senior adult

No variant requirements are available.